Mumbai: IOL Chemicals and Pharmaceuticals Ltd, a leading manufacturer of pharmaceutical APIs and speciality chemicals, announced its financial results for quarter and nine months year ended 31st December, 2024.
Standalone Q3 & 9M FY25 Financial Highlights (₹ in Crore)
|
Particulars |
Q3 FY25 |
Q2 FY25 |
% QoQ |
Q3 FY24 |
% YoY |
9M FY25 |
9M FY24 |
% YoY |
|
Total Income |
527.37 |
532.18 |
-0.90 |
528.77 |
-0.26 |
1569.31 |
1651.42 |
-4.97 |
|
EBITDA |
50.94 |
47.99 |
6.15 |
52.86 |
-3.63 |
157.11 |
203.99 |
-22.98 |
|
EBITDA Margin (%) |
9.66% |
9.02% |
64 |
10.00% |
-34 bps |
10.01% |
12.35% |
-234 bps |
|
PAT |
20.55 |
19.15 |
7.31 |
23.23 |
-11.54 |
69.38 |
107.23 |
-35.30 |
|
PAT Margin (%) |
3.90% |
3.60% |
30 |
4.39% |
-49 bps |
4.42% |
6.49% |
-207 bps |
Commenting on the performance, Mr Vikas Gupta, Joint Managing Director said, We are pleased to report our Q3FY25 Results as despite challenges such as pricing pressures, stagnant demand, and intense market competition, the company has successfully maintained stable and sustainable performance. This resilience reflects our strategic approach and adaptability in a dynamic business environment.
Confident of our resilient performance, the Board has declared an interim dividend of Rs. 4/- (40%) per share of face value of Rs 10 each for financial year 2024-25 and fixed a Record Date for 18th February 2025 for ascertaining the entitlement. Moving forward, we remain committed to our long-term vision by focusing on market diversification and expansion to unlock new growth opportunities. Additionally, we are implementing comprehensive cost optimization measures to enhance operational efficiency, improve profitability, and reinforce our competitive position.